Showing results (1-10 of 16) with videos related to
Sort By:
Pageof 2
The Journal of Biological Chemistry|February 4, 2003
Triiodothyronine increases brain natriuretic peptide (BNP) gene transcription and amplifies endothelin-dependent BNP gene transcription and hypertrophy in neonatal rat ventricular myocytesFaquan Liang, Paul Webb, Adhirai Marimuthu, et al.Molecular Endocrinology (Baltimore, Md.)|January 31, 2002
TR surfaces and conformations required to bind nuclear receptor corepressorAdhirai Marimuthu, Weijun Feng, Tetsuya Tagami, et al.Nuclear Receptor|August 9, 2003
ERbeta Binds N-CoR in the Presence of Estrogens via an LXXLL-like Motif in the N-CoR C-terminusPaul Webb, Cathleen Valentine, Phuong Nguyen, et al.Proceedings of the National Academy of Sciences of the United States of America|March 16, 2006
Structural characterization of autoinhibited c-Met kinase produced by coexpression in bacteria with phosphataseWeiru Wang, Adhirai Marimuthu, James Tsai, et al.Proceedings of the National Academy of Sciences of the United States of America|May 18, 2005
The crystal structures of human steroidogenic factor-1 and liver receptor homologue-1Weiru Wang, Chao Zhang, Adhirai Marimuthu, et al.Therapeutic Advances in Medical Oncology|July 2, 2019
Phase Ib study of the combination of pexidartinib (PLX3397), a CSF-1R inhibitor, and paclitaxel in patients with advanced solid tumorsRobert Wesolowski, Neelesh Sharma, Laura Reebel, et al.The Journal of Steroid Biochemistry and Molecular Biology|March 26, 2003
Design of thyroid hormone receptor antagonists from first principlesPaul Webb, Ngoc-Ha Nguyen, Grazia Chiellini, et al.Neuro-Oncology|October 10, 2015
Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II studyNicholas Butowski, Howard Colman, John F De Groot, et al.Proceedings of the National Academy of Sciences of the United States of America|March 16, 2013
Design and pharmacology of a highly specific dual FMS and KIT kinase inhibitorChao Zhang, Prabha N Ibrahim, Jiazhong Zhang, et al.Nature|October 16, 2015
RAF inhibitors that evade paradoxical MAPK pathway activationChao Zhang, Wayne Spevak, Ying Zhang, et al.Pageof 2